Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

As of 2026-11-21 · 12/15 boxes filled from SEC filings and market data

Report price $39.23 (close 2026-11-20)

Conclusion: WATCH

Conviction medium · base case +27% · downside -24% · upside +33%

The market is pricing Teva off its cash engine and brand mix rather than a generic-only profile: the $45.73B enterprise value is 2.65x TTM revenue and 18.9x TTM EBITDA, while free cash flow is $1.24B and the quality score is 34/100. That supports a WATCH label: the base case is not far enough above the current price to justify more conviction, and the EBITDA multiple already sits above the peer set. The base case is $49.88 (+27.1%), built on EV/Sales at 3.37x, the peer median across five peers; the downside is $30.02 (-23.5%), built on -10.0% sales at a compressed EV/Sales of 2.25x (today 2.65x); and the upside is $52.29 (+33.3%), built on a re-rating to 3.37x on the cited dated catalyst. Those cases bracket a balanced setup, with the base requiring the peer median multiple rather than a re-rating beyond it. The reverse DCF still prices +10.3% annual revenue growth for 10 years, against +4.3% in the latest fiscal year, so the market is already assuming a meaningful acceleration.

Key numbers

  • Share price: $39.23
  • Market cap: $45.77B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $17.23B
  • EV / EBITDA (TTM): 18.9x
  • P/E (TTM): 90.5x
  • FCF yield: 2.7%
  • Price / book: 5.74x
  • Earnings-quality flags (TTM): Restructuring charges -$150.0M (30% of net income); Debt extinguishment -$224.0M (44% of net income); Income tax benefit on a pre-tax profit (e.g. a valuation allowance release), against a 21% charge $212.0M (42% of net income)
  • P/E, adjusted (TTM): 68.5x
  • P/E, operating (tax-normalized) (TTM): 111.6x
  • EV / FCF (TTM): 37.0x
  • Revenue growth (latest fiscal year): +4.3%
  • ROIC (TTM): 13.6%
  • WACC: 8.0%
  • Economic profit spread: +5.7 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Teva is a three-segment generics-plus-innovative biopharmaceutical maker (United States, Europe, International Markets) with ~34,000 employees in 57 markets, a US distribution arm (Anda), and a manufacturing base of 33 finished-dosage plants in 21 countries. Between the FY2020 10-K and the FY2025 10-K the language and portfolio shifted from 'specialty medicines' and 500+ US generics to 'innovative medicines' and 350+ US generics, with manufacturing and product pruning, the March 2025 Japan venture divestiture, and a May 2023 'Pivot to Growth' plan targeting ~$700M of net savings through 2027. On the XBRL facts I have (all post the 2016 acquisition period), revenue ran $16.66B (FY2020) down to a $14.93B trough (FY2022) and back to $17.26B (FY2025) with $17.23B TTM to Sep 2026, while GAAP operating income swung between -$3.57B (FY2020) and +$2.16B (FY2025). Operating cash flow was steadier than earnings: $1.22B-$1.77B every year, with capex of roughly $0.5B.

  2. ✓ 2. Competitive advantage

    The filings describe a low-pricing-power business, not a moat-protected one: generics were $9,421M, or 55% of FY2025 revenue, and the company states generic medicines are 'generally less profitable' with price erosion in each segment. Scale shows up in Europe (pan-European footprint) and International Markets, but not in pricing, and operating income swung from -$3.57B (FY2020) to $2.16B (FY2025) with $1.44B on the TTM to 2026-09-30. The only durable line is cash generation, $1.22B-$1.77B of operating cash flow every year from FY2020 to the TTM, and cost cuts (headcount 37,851 at 2023-12-31 to 33,950 at 2025-12-31) are the main lever offered against price erosion.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 revenue was $4,395 million, down 2% year over year, as U.S. generic products fell 39% on lenalidomide competition while AUSTEDO, AJOVY and UZEDY grew. Gross margin expanded and non-GAAP operating income rose, but GAAP operating income fell on higher legal settlements and impairments. The earnings release raised FY2026 revenue and brand outlooks, and the 10-Q reported no material risk-factor changes from the FY2025 10-K. Q3 operating cash flow fell to $241 million, while free cash flow was $495 million.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans